...Case Study TEVA Strengthens Security for Software Assets with MKS Integrity “One of the main measures for success in the implementation of the MKS Integrity Suite was the reduction in the amount of paper and forms that get manually pushed from person to person. By simply automating service request forms and routing them via electronic workflows we have become much more effective, and dramatically reduced our time spent managing projects.” Tom Loane, Chief Information Officer , TEVA Pharmaceuticals Company Overview TEVA USA is a wholly-owned subsidiary of TEVA Pharmaceutical Industries Ltd., Israel’s largest pharmaceutical manufacturer operating globally in 30 countries on 5 continents. TEVA is among the top 20 pharmaceutical companies and the largest generic pharmaceutical companies in the world. The company has approximately 14,000 employees worldwide with production facilities in Israel, North America, Europe and Mexico. TEVA USA has an aggressive Research & Development effort and one of the best overall ANDA approval records in the industry. The company’s mission is to play a leading role in the transformation of the U.S. healthcare system through its preeminence in the development, manufacturing and marketing of pharmaceuticals. The Challenge As a pharmaceutical company operating in the U.S., TEVA must comply with Food and Drug Administration (FDA) regulations. The FDA requires stringent application development and change control practices surrounding software...
Words: 1059 - Pages: 5
...the island to analyze the possibility of the plans of the Teva Pharmaceuticals to increase its presence in the island. Determining Factors Affecting the Decision Implementation The disaster threats relative to the geographic location of Kava pose considerable risks to any business operating in the island. Teva Pharmaceuticals will not be exempted from that. The threats also pose real danger to the health of the people of Kava. The risks from the disaster threats could significantly affect the health of the population particularly if accessibility to affordable health and medical supplies is difficult. The threats from AIDS/HIV alone could be devastating but the threat could be eased with available protective device such as affordable and easy accessible condom sheaths. The situation in Kava could be a great opportunity for the Teva Pharmaceuticals to expand its mission which is “to play a leading role in the transformation of the U.S. healthcare system through its pre-eminence in the development, manufacture and marketing of generic pharmaceuticals (TEVA USA., 2010, para 2)”. The company can expand that mission to the healthcare system of Kava Island highly vulnerable to many threats particularly storm, tsunami, earthquake, flood, fire, petroleum spills, AIDS/HIV, and avian flu (University of Phoenix, 2010). The condition of Kava may not be highly favorable but the island also has some benefits to offer to Teva...
Words: 1991 - Pages: 8
...The background of the company with a lifecycle analysis Amgen is a worldwide biotechnology company that develops and distributes medicines that treat millions of seriously ill patients. They were early pioneers starting in 1980, and have grown to be the world’s largest independent biotech headquartered out of Thousand Oaks, California. They currently have a dozen successful FDA approved and profitable drugs (1). Amgen went public in 1984 and currently trade on the NASDAQ under the symbol AMGN. Amgen is officially listed under the Healthcare sector and further classified under the Biotechnology industry (2). They have experienced unprecedented organic growth but also acquired several other public and private companies over the years that had a product with potential, but not the resources to complete the brutal FDA requirements, submission, and approval process successfully. Operating risks are low with Amgen; new drugs are studied under clinical trials for years before approaching the FDA for approval. Once FDA approval is secured, Amgen enjoys long contracts where the drug cannot be copied and sold under a generic brand for a decade or more. Matter of fact, they have won several infringement lawsuits protecting their technology over the years. As stated earlier, they have several approved medicines that are already in the market where they have absolute market penetration. However, over the years contracts expire, and new drugs must be developed. These new sources of...
Words: 1619 - Pages: 7
...Project Presentation on Dr Reddy’s Laboratories Group 4: Abhishek Aggrawal Anik Bairagi Nishant Sawan Kumar Varun Saini 1 0911074 0911079 0911109 0911127 0911138 Global Pharmaceutical Market - Overview The increasing generics share and shift of the industry towards emerging markets is causing margin pressure on global pharma players and forcing them to invest in these new markets Global Pharmaceutical Market The pharmaceutical market was $ 820Bn in Other Patented 86% 83% 81% 79% 2009, growing at a CAGR of 9% over 200309 Generics is growing at double the rate of the Generics 2004 2006 2008 2010E total industry (18% CAGR), while Patented drugs market is growing at 7% India 1% Geographical Market Share Middle Africa 1% East 1% CIS 2% Others 12% US 42% Top 10 countries account for 73% of sales US accounts for 42% of the world sales While the US sales are growing at only 1-2% CAGR, growth in emerging markets is over 10% Latin America 6% South East and East Asia 6% EU 29% Source: Centrum Research Report on Pharma Industry 2009; 2 Key Growth Drivers for Global Pharmaceutical Market 1 Sluggish Growth in Mature Markets Economic slowdown leading to reduced healthcare spending Top brands’ patent expiries and very few new product launches Decentralization of government healthcare budgets. High healthcare expenditure by government 2 Faster Growth in Emerging Markets Broader public and private...
Words: 3256 - Pages: 14
...company’s liabilities, ownership equity and assets at a certain moment (a “snapshot”) in time within the business’ calendar year. An Income Statement however documents income (revenue) and expenses over particular period which can be done quarterly or at the end of the financial year. Ultimately, although the Income Statement and the Balance Sheet are closely related and therefore complement each other, the information documented in each is so different that they are not substitutable. I will be using the 2012 Annual Report of Fenner plc, FTSE250 manufacturing company, along with accounting policies and theory to highlight how the two financial statements provide complementary but different information. Moreover, I will briefly compare a TEVA Pharmaceuticals Ltd Q2 2013 quarterly report to highlight differences between information shown annually and quarterly. I will provide a link to the .pdf version of the annual reports in my appendix, while all the “Exhibits” will be excerpts from the reports. Firstly it is important to know in detail the role each financial statement has. The purpose of the Income Statement, or profit and loss account, is to “measure how much profit (wealth) the business has generated over a period”. This is done by identifying both the revenue that the business generates during every day operations and the expenses incurred during these day-to-day operations. Any gain in economic benefits (revenue) will “result in either an increase in assets (cash or amounts owed...
Words: 1840 - Pages: 8
...9 -3 1 3 -0 1 6 REV: AUGUST 1, 2014 REGINA E. HERZLINGER NATALIE KINDRED Shanghai Pharmaceuticals With 2011 revenues of $8.67 billion, 1 Shanghai Pharmaceuticals (SPH), a vertically integrated Chinese pharmaceutical conglomerate, produced active pharmaceutical ingredients (APIs), chemical and biological drugs, and traditional Chinese medicines (TCMs); distributed its own and other drug makers’ products to hospitals and other customers; and operated a chain of retail pharmacies. The company—essentially a collection of subsidiaries operating under a unified management structure— was formed through the 2009 merger of several state-owned enterprises (SOEs), part of a broad policy effort in China to streamline state assets, consolidate the fragmented pharmaceutical sector, and enhance the global competitiveness of domestic firms. Emblematic of China’s hybrid economic policies, SPH had both government and private shareholders and competed in a historically statecontrolled industry that was adapting to the growing influence of market forces. SPH’s initial public offering (IPO) on the Hong Kong Stock Exchange in 2011 marked an important step in its quest to transform from a traditional SOE into a market-oriented company. While working to expand SPH’s domestic footprint, the company’s leadership was also considering a potential acquisition of a U.S. or European drug producer, an unusual move for a Chinese company. SPH could leverage such an acquisition to learn from Western research...
Words: 12061 - Pages: 49
...DECEMBER 21, 2012 CORPORATES RATING METHODOLOGY Global Pharmaceutical Industry Summary This rating methodology explains Moody’s approach to assessing credit risk for companies in the pharmaceutical industry globally. This document is intended to provide general guidance that helps companies, investors, and other interested market participants understand how key qualitative and quantitative risk characteristics are likely to affect rating outcomes for companies in the pharmaceutical industry. This document does not include an exhaustive treatment of all factors that are reflected in Moody’s ratings but should enable the reader to understand the qualitative considerations and financial information and ratios that are usually most important for ratings in this sector. This rating methodology replaces 1 the Global Pharmaceutical Industry Methodology published in October 2009. While reflecting many of the same core principles as the 2009 document, this update provides a more transparent presentation of the rating considerations that are usually most important for companies in this sector and incorporates refinements in our analysis that better reflect key credit fundamentals of the industry. No rating changes will result from publication of this rating methodology. This report includes a detailed rating grid and illustrative mapping examples that compare historical performance on factors in the grid to ratings of companies covered by this methodology. The purpose of the...
Words: 13613 - Pages: 55
...142 156 171 60 40 20 Source: Datamonitor "The vast projected increase in expenditure will offer pharmaceutical companies enormous opportunities to reap commercial reward if they are strategically placed to take advantage of these possibilities" 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 0 Business Insights Business Insights is a series of management reports designed to help you make informed, timely business decisions. We understand the problems facing today's managers in taking your business into the next millennium, and appreciate the importance of the role of accurate, up-to-date, incisive market and company analysis. We help you to crystallise your business decision making. Business Insights’ reports are authored by independent experts in their fields and offer results from our unique primary research methodology. Our authors' leading positions allow them to interview key industry executives and to quantify which issues will be of greatest strategic significance in an industry's future. The results of our analysis and recommendations will help you to evaluate the impact of these issues on your business, and plan to position yourselves to take the greatest advantage of opportunities which will arise in tomorrows commercial environment. The strength of our Healthcare research and analysis function is derived from its access to unparalleled databases and libraries of information, its proprietary analytic...
Words: 3014 - Pages: 13
...convinced many nations to reconsider their energy policy. Despite all of this, globalization, even though criticized, is still active. Firms are moving to the new emerging economies in order to capture the consumption appetite of the growing middle classes. It is still relevant and important to put together all aspects of global strategic management. This third edition is still about global firms and global management. Its objective remains to help undergraduate and graduate students, as well as company executives, to understand the main issues that companies and their managers confront when they ‘go global’ or ‘manage globally’, and to cope with these issues. Data have been updated and several new cases and examples added. At the end of each chapter there are now one or two new ‘Mini-Cases’ that students may discuss in class. The book...
Words: 2794 - Pages: 12
...Decisions………………………………………………5-7 Possible Future Scenarios…………………………………………………………...7-8 Recommendations for Changes in Culture, Leadership, and/or Structure…………..8-9 Summary/Conclusions………………………………………………………………...9 Reference…………………………………………………………………………10-11 Introduction/Overview To start a company, a person or group of people must realize that it is a bumpy ride from the beginning, and that only those who are prepare enough will succeed. They have to follow multiple rigorous steps and come up with innovative strategies to prove that they have what it takes to be successful in the business. Pfizer Inc. is a company that has proven itself throughout time. They are the world’s largest research based pharmaceutical company and were also recognized by Fortune magazine as the world’s largest pharmaceutical company by profit and second largest by revenue, only next to Johnson and Johnson (Fortune, 2013). Pfizer Inc. have evolve throughout the years along with science and have been responsible for the discovery and marketing of some of the world’s most innovative drugs like, Lipitor (use to decrease cholesterol), Lyrica (use for treatment of fibromyalgia), Zithromax (a renown antibiotic), and many others. Although they focus mainly on human drugs, they also produce animal and consumer healthcare products. The company have apply their science and global resources to help and make a positive impact in the quality of life and health of millions of people and animals around the world. To prove...
Words: 2350 - Pages: 10
...Executive Summary: Pfizer-Wyeth Merger Deal Overview: On January 25, 2009, Pfizer and Wyeth entered into the merger agreement, pursuant to which, subject to the terms and conditions set forth in the merger agreement, Wyeth will become a wholly-owned subsidiary of Pfizer. Upon completion of the merger, each share of Wyeth common stock issued and outstanding will be converted into the right to receive, subject to adjustment under limited circumstances, a combination of $33.00 in cash, without interest, and 0.985 of a share of Pfizer common stock in a taxable transaction. Pfizer will not issue more than 19.9% of its outstanding common stock at the acquisition date in connection with the merger. The exchange ratio of 0.985 of a share of Pfizer common stock will be adjusted if the exchange ratio would result in Pfizer issuing in excess of 19.9% of its outstanding common stock as a result of the merger Deal Terms Breakdown: Transaction Value Transaction Consideration Purchase price per WYE share $50.19 Existing Cash Used $22,213 32.7% Cash per WYE share $33.00 New Debt $22,500 33.1% PFE stock value per WYE share $17.19 Total Cash $44,713 65.8% PFE shares per WYE share 0.985 Stock Consideration $23,289 34.2% Premium to 1/23/09 WYE price 29.3% Total Consideration $67,303 100.0% Total WYE shares (MM,diluted) 1,341 Total Equity...
Words: 8308 - Pages: 34
...A “Calibrated Approach”: Pharmaceutical FDI and the Evolution of Indian Patent Law Web version: August 2007 Authors: Katherine Connor Linton and Nicholas Corrado1 Abstract India has charted its own intellectual property (IP) path over the last 35 years, attempting to foster the growth of a domestic pharmaceutical industry and access to medicine while, more recently, also addressing the requirements of the international IP regime. Multinational companies (MNCs) have responded to India’s movement towards compliance with the W TO intellectual property agreement, TRIPS, by increasing the quantity and quality of foreign direct investment (FDI) in the areas of pharmaceutical research and development (R&D) and manufacturing. By contrast, MNCs have adopted a more cautious attitude toward the patenting and commercialization of new pharmaceutical products in India, waiting to see how Indian courts and patent offices interpret the new laws, and awaiting the enactment of longdebated data protection legislation. The ultimate success of the Indian “calibrated approach” to fostering the domestic industry and access to medicine while also addressing international IP requirements remains to be seen. 1 Katherine Connor Linton (katherine.linton@usitc.gov) is the International Trade Analyst for Intellectual Property and Nicholas Corrado was a law student intern in the Office of Industries of the U.S. International Trade Commission (USITC). The views expressed are those of Ms. Linton and...
Words: 6873 - Pages: 28
...Pharmaceutical Supply Chain Abstract • The global pharmaceutical supply chain is very complex and critical to a $650 billion dollar value industry which ensures the world population has necessary medicines. • Manufacturers have the responsibility to produce sufficient quantities of drugs to meet a growing global demand while maintaining quality to ensure safety. • Global and local regulatory agencies around the world have a daunting task to monitor manufacturers, raw material suppliers, and stem counterfeit pharmaceutical production. • Wholesale distributors, importers, and retail pharmacies have a large amount of power in the supply chain as they pull the demand from the manufacturers and provide the medicines to end-consumers. • In a changing industry where there are fewer blockbuster drugs and increasing use of generic offerings, manufacturers as well as participants at all levels of the supply chain must look for areas to improve efficiencies to be profitable in the long-run. Pharmaceutical Supply Chain Analysis 2 Introduction A transparent and efficient pharmaceutical supply chain contributes significantly towards improving the availability of essential medications. The reality across the world is that pharmaceutical supply and distribution consists of different stakeholders from both the public and private sectors to create complex systems. In a heavily regulated field, globalization has placed increasing demands on regulatory agencies to ensure the safety and...
Words: 6177 - Pages: 25
...Strategy 2 2. Pfizer's Road Map 4 2.1. Pfizer's Acquisitions Rational 4 3. The strategy behind the acquisition 5 3.1. Acquisition Motives 5 3.2. M&A vs. Alliance 5 4. Target Identification 7 4.1. Protalix - an R&D Acquisition 9 5. Synergy Analysis 10 6. Standalone, Synergy and Premium Valuations 12 6.1. Market Value 12 6.2. Trading and Transaction Multiples Valuations 12 6.3. Discounted Cash Flow (DCF) Valuation 14 6.3.1. DCF Methodology and Assumptions 14 6.3.2. Summary of the Standalone and the Synergy DCF Valuation 15 6.4. Premium 16 6.5. Walk-away Price, Net Value Creation and Financial Feasibility 17 Part 2 - The Integration Plan 18 Bibliography 21 APPENDIXES 22 Appendix 1 - Pfizer's Executive Leadership Team 23 Appendix 2 - Pfizer's Organizational Structure Scheme 24 Appendix 3 - Five Forces Analysis for the Pharmaceutical Industry 25 Appendix 4 - Pfizer's PEST Analysis 27 Appendix 5 - Level of Competition Between the Acquirers & the Uniqueness of the Acquired Company 31 Appendix 6 - Acquisition Motives 33 Appendix 7 - Protalix Management and Board of Directors 35 Appendix 8 - Technology Adoption Lifecycle 36 Appendix 9 - Pfizer's SWOT Analysis 36 Appendix 10 - Protalix's Financials 38 Appendix 11 - About the Valuation Methods 40 Appendix 12 - List of Companies and Their Multiples 41 Appendix 13 - Complete Results of Multiples Valuations 42 Appendix 14 - DCF Data and Assumptions 43 Appendix...
Words: 10031 - Pages: 41
...Venture Capital Funding Proposal Venture Capital Funding Proposal 08 Fall 08 Fall EXECUTIVE SUMMARY Mobileye N.V. is a growing competitor in the Advanced Driver Assistance Systems (ADAS) industry. Mobileye is the successful developer of the EyeQ software on a low cost, automotive standards chip that allows for real time interpretation of data on visual surroundings, assisting drivers in prevention of collisions and identification of threats. The single camera system and strong relationship that Mobileye maintains with currently 18 original equipment manufacturers (OEMs) means the product is low cost, but still maintains quality and effectiveness. Mobileye being the developer of its flagship product, the EyeQ, with primary costs to production being the purchase of microchips on which the software is reproduced, means that cost of revenues is low, output is highly scalable and so Mobileye is capable of devoting substantial portions of future earnings to further research, improving existing products and gaining further growth through introduction of other ADAS products. This suggests extremely positive growth potential for Mobileye over the medium term. The ADAS market in which Mobileye operates shows a potential compound annual growth rate of more than 50% until 2018 (vli Ltd, 2014). This expected growth is attributed to several strong factors. Firstly, rapid technological progress has substantially lowered costs to production, meaning a much broader market of vehicles...
Words: 6152 - Pages: 25
